【礼来(LLY.US)1类新药在中国启动新III期临床】智通财经APP获悉,8月17日,药物临床试验登记与信息公示平台官网显示,礼来(LLY.US)登记了一项Brenipatide注射液在成人抑郁症参与者中的III期临床研究。Insight数据库显示,Brenipatide是全球首个启动抑郁症III期临床的GLP-1类产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.